|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM116 |
Gene summary for TMEM116 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM116 | Gene ID | 89894 |
| Gene name | transmembrane protein 116 | |
| Gene Alias | TMEM116 | |
| Cytomap | 12q24.12-q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q8NCL8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 89894 | TMEM116 | LZE2T | Human | Esophagus | ESCC | 1.03e-02 | 3.32e-01 | 0.082 |
| 89894 | TMEM116 | LZE4T | Human | Esophagus | ESCC | 1.05e-26 | 7.99e-01 | 0.0811 |
| 89894 | TMEM116 | LZE7T | Human | Esophagus | ESCC | 5.98e-07 | 4.90e-01 | 0.0667 |
| 89894 | TMEM116 | LZE24T | Human | Esophagus | ESCC | 2.92e-07 | 1.95e-01 | 0.0596 |
| 89894 | TMEM116 | P2T-E | Human | Esophagus | ESCC | 8.08e-19 | 3.31e-01 | 0.1177 |
| 89894 | TMEM116 | P4T-E | Human | Esophagus | ESCC | 5.70e-10 | 2.91e-01 | 0.1323 |
| 89894 | TMEM116 | P5T-E | Human | Esophagus | ESCC | 1.66e-02 | 6.62e-02 | 0.1327 |
| 89894 | TMEM116 | P8T-E | Human | Esophagus | ESCC | 9.97e-07 | 1.57e-01 | 0.0889 |
| 89894 | TMEM116 | P9T-E | Human | Esophagus | ESCC | 1.06e-23 | 5.81e-01 | 0.1131 |
| 89894 | TMEM116 | P10T-E | Human | Esophagus | ESCC | 2.37e-12 | 1.82e-01 | 0.116 |
| 89894 | TMEM116 | P11T-E | Human | Esophagus | ESCC | 1.93e-02 | 2.06e-01 | 0.1426 |
| 89894 | TMEM116 | P12T-E | Human | Esophagus | ESCC | 2.44e-10 | 2.51e-01 | 0.1122 |
| 89894 | TMEM116 | P15T-E | Human | Esophagus | ESCC | 9.42e-25 | 5.94e-01 | 0.1149 |
| 89894 | TMEM116 | P16T-E | Human | Esophagus | ESCC | 1.26e-05 | 1.94e-01 | 0.1153 |
| 89894 | TMEM116 | P20T-E | Human | Esophagus | ESCC | 3.24e-04 | 2.66e-01 | 0.1124 |
| 89894 | TMEM116 | P21T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.08e-01 | 0.1617 |
| 89894 | TMEM116 | P22T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.04e-01 | 0.1236 |
| 89894 | TMEM116 | P23T-E | Human | Esophagus | ESCC | 3.96e-04 | 1.69e-01 | 0.108 |
| 89894 | TMEM116 | P26T-E | Human | Esophagus | ESCC | 9.02e-11 | 1.60e-01 | 0.1276 |
| 89894 | TMEM116 | P27T-E | Human | Esophagus | ESCC | 3.02e-26 | 4.00e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM116 | SNV | Missense_Mutation | novel | c.714N>G | p.Phe238Leu | p.F238L | Q8NCL8 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| TMEM116 | SNV | Missense_Mutation | rs759014592 | c.860C>T | p.Thr287Met | p.T287M | Q8NCL8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.366N>A | p.Ser122Arg | p.S122R | Q8NCL8 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.343N>A | p.Gln115Lys | p.Q115K | Q8NCL8 | protein_coding | tolerated(0.52) | benign(0.001) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | rs374733446 | c.694C>T | p.Arg232Cys | p.R232C | Q8NCL8 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.434N>G | p.Phe145Cys | p.F145C | Q8NCL8 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.137N>T | p.Thr46Met | p.T46M | Q8NCL8 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.800N>C | p.Val267Ala | p.V267A | Q8NCL8 | protein_coding | deleterious(0) | benign(0.269) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | novel | c.557N>A | p.Gly186Asp | p.G186D | Q8NCL8 | protein_coding | deleterious(0.04) | benign(0.188) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM116 | SNV | Missense_Mutation | c.802C>A | p.Leu268Ile | p.L268I | Q8NCL8 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |